Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

J&J Expects A Commercial COVID-19 Vaccine Market By Late 2022/2023

Oct 19 2021

• By Jessica Merrill

Sales growth concept — J&J reported steady Q3 sales growth • Source: Alamy

Related Content

Janssen Gets US FDA Panel Nod For Additional COVID Vaccine Shot – But Is It A ‘Booster’?

Oct 16 2021

J&J's COVID-19 Vaccine On Track To Generate $2.5bn This Year

Jul 21 2021

J&J CEO Gorsky Handing Over The Reins To Vice Chairman Duato

Aug 20 2021

J&J's Longtime R&D Head Stoffels To Retire, Raising The Leadership Transition Stakes

Oct 12 2021

J&J Q1 Financials Are All About COVID-19 Progress And Impact

Apr 14 2020

Related Companies

Johnson & Johnson

Pfizer Inc.

BioNTech SE

Moderna, Inc.

Additional Topics

Sales & Earnings Coronavirus COVID-19 Business Strategies Leadership BioPharmaceutical

More from Earnings

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window